1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022


Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Otsuka’s Abilify (aripiprazole) is a quinolone piperidine derivative with partial agonist properties at the D2 dopaminergic receptor. By acting as a partial agonist at this dopamine receptor subtype, Abilify presents a unique mechanism within the schizophrenia drug portfolio: partial D2 agonism modulates dopaminergic activity in areas where dopamine may be high or low, such as in the mesolimbic and mesocortical areas of the schizophrenic brain.


- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Abilify including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Abilify for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Abilify performance
- Obtain sales forecast for Abilify from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Diagnosis 14
4.1.1 Subjective Assessments 15
4.1.2 Disease Subtypes 16
4.2 Treatment Overview 19
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 21
4.2.2 Maintenance Treatment of Schizophrenia 22
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Abilify (aripiprazole) 26
6.1 Overview 26
6.2 Efficacy as an Acute Treatment 28
6.3 Efficacy as a Maintenance Treatment 28
6.4 Safety 29
6.5 SWOT Analysis 30
6.6 Forecast 31
7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 35
7.3 Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Diagnosis and Treatment Rates 36
7.4.2 Adherence Rates 37
7.4.3 General Pricing Assumptions 37
7.4.4 Drug Assumptions 38
7.4.5 Generic Erosion 39
7.5 Key Opinion Leaders 40
7.6 About the Authors 41
7.6.1 Author 41
7.6.2 Reviewers 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 13
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 16
Table 3: Development-Based Classification of Antipsychotic Drugs 19
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 20
Table 5: Guidelines for the Treatment of Schizophrenia 21
Table 6: Leading Branded Treatments for Schizophrenia, 2013 25
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 25
Table 8: Product Profile - Abilify 27
Table 9: Abilify SWOT Analysis, 2014 30
Table 10: Global Sales Forecast ($m) for Abilify, 2012-2022 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.